Cancer

Caresyntax and Qaelon Medical announce data intelligence partnership to address devastating impact of surgical leaks

SAN FRANCISCO and STRASBOURG, France, Jan. 9, 2025 /PRNewswire/ -- Caresyntax, the world-leading developer of surgical intelligence platforms and Qaelon…

12 months ago

J.P. Morgan Healthcare Conference 2025: Genomics Announces Dr Jose-Carlos Gutiérrez-Ramos as New Board Member to Accelerate Global Expansion and Life Sciences R&D Growth

Dr Jose-Carlos Gutiérrez-Ramos is the Chief Science Officer at Danaher Corporation. He has held senior drug discovery roles at Pfizer,…

12 months ago

Outcomes Matter Innovations (OMI) and Regional Cancer Care Associates (RCCA) announce Co-Development Agreement to enhance quality and reduce cancer care costs through OMI Technology

JERSEY CITY, N.J., Jan. 9, 2025 /PRNewswire/ -- Outcomes Matter Innovations, LLC ("OMI") today announced a co-development agreement with Regional…

12 months ago

RyboDyn, Inc. Announces Discovery of a Cryptic Human Proteome and $4M Pre-Seed Financing

Dark genome biotech company RyboDyn closes pre-seed fundraise from leading global investors to advance cancer immunotherapy SAN DIEGO, Jan. 9,…

12 months ago

SimBioSys Appoints Stacey Stevens as President and CEO

Stevens brings decades of healthcare leadership and innovation to TechBio company at the forefront of advancing digital precision medicine to…

12 months ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025…

12 months ago

Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential

FMC-220 is a first-in-class covalent activator of p53Y220C designed to address potency and tolerability challenges of non-covalent approachesIn preclinical studies,…

12 months ago

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health…

12 months ago

Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a…

12 months ago